FDA Approves Novartis Kymriah^® CAR-T Cell Therapy for Adult Patients with Relapsed or Refractory Follicular Lymphoma

Novartis announced the FDA has granted accelerated approval for Kymriah® for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.